daLUXendin544

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NamedaLUXendin544
Drug Alias NamedaLUXendin-544
ClassificationDiagnostic agent (In vivo)Small molecules > Heterocyclic drugs
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide Receptor
Therapy Area/IndicationsContrast agents
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of BirminghamNovo Nordisk A/SUniversity Of Oxford
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesN/A
Active IndicationsContrast agents
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A